Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) were up 5.1% during trading on Thursday . The stock traded as high as $6.68 and last traded at $6.63, with a volume of 156,759 shares trading hands. The stock had previously closed at $6.31.

Several equities analysts have recently issued reports on the stock. Stifel Nicolaus decreased their price target on shares of Argos Therapeutics from $16.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, March 30th. Zacks Investment Research raised shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a report on Friday, April 1st. Roth Capital boosted their price target on shares of Argos Therapeutics from $11.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, April 19th. Needham & Company LLC reaffirmed a “buy” rating on shares of Argos Therapeutics in a research note on Saturday, April 23rd. Finally, FBR & Co reaffirmed a “buy” rating on shares of Argos Therapeutics in a research note on Saturday, May 14th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $11.84.

The firm’s market capitalization is $171.66 million. The company has a 50-day moving average price of $6.18 and a 200-day moving average price of $5.47.

Argos Therapeutics (NASDAQ:ARGS) last released its quarterly earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by $0.01. Analysts anticipate that Argos Therapeutics Inc. will post ($1.74) earnings per share for the current year.

Argos Therapeutics, Inc (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.